Agreements reached under this partnership
Business alliance- 1
Research, development and commercialization targeting multiple targets in diabetes and metabolic diseases
- 2
Leveraging the Company's structure-based drug discovery platform, which has strengths in G protein-coupled receptors (GPCRs), together with Eli Lilly and Company's expertise in a broad range of pharmaceutical development, commercialization and therapeutic areas
- 3
Identification of small-molecule compounds targeting GPCRs, structural analysis of receptors in the presence of those compounds and, as a result, elucidation of binding sites
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact on the Company's consolidated results for the fiscal year ending December 2026 has already been reflected in the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026
| Item | Details |
|---|---|
| Name of alliance partner | Eli Lilly and Company (イーライリリー社) |
| Alliance partner's business activities | Expertise in a broad range of pharmaceutical development, commercialization and therapeutic areas |
| Type of alliance | Business alliance |
| Details of the alliance | Research, development and commercialization targeting multiple targets in diabetes and metabolic diseases, Leveraging the Company's structure-based drug discovery platform, which has strengths in G protein-coupled receptors (GPCRs), together with Eli Lilly and Company's expertise in a broad range of pharmaceutical development, commercialization and therapeutic areas, Identification of small-molecule compounds targeting GPCRs, structural analysis of receptors in the presence of those compounds and, as a result, elucidation of binding sites |
| Alliance start date | 2022 (launch) |
| Impact on Business Performance | The impact on the Company's consolidated results for the fiscal year ending December 2026 has already been reflected in the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026 |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The achievement is described as demonstrating the utility of the Company's NxWave™ platform in identifying small-molecule compounds targeting GPCRs, analyzing receptor structures in the presence of compounds and elucidating binding sites.